Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + BR-I in R/R Mantle Cell Lymphoma
NCT03295240Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2017
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in mantle cell lymphoma (MCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose at 1 year and Treatment related toxicity at 1 year. Started Sep 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03295240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295240.